TICKERNERD
Menu
RNAHealthcare · Biotechnology

RNA Stock Forecast: Atrium Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$13

The 4 Wall Street analysts covering Atrium Therapeutics, Inc. hold a median 12-month price target of $25 — +89.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$225.8M
Ticker Nerd rank
5 / 100
Median analyst target
$25
Analysts covering
4
Ticker Nerd rank

RNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atrium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
5 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
76
Size
67
Momentum
13
Issuance
12
Growth
8
Accruals
8
Value
7
Quality
4
Volatility
4

Revisions (76): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNA, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $25Median $25High $25

The green dot is the last close — the median target sits +89.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
6 Aug 2026HC Wainwright & Co.InitiatesBuy$25
6 Aug 2026HC Wainwright & Co.InitiatesBuy—
18 June 2026Cantor FitzgeraldInitiatesOverweight$25
18 June 2026Cantor FitzgeraldInitiatesOverweight—
15 May 2026Leerink PartnersInitiatesOutperform—
11 Mar 2026Wells FargoInitiatesOverweight—
11 Nov 2025Chardan CapitalMaintainsNeutral—
29 Oct 2025TD CowenDowngradeHold—
28 Oct 2025Chardan CapitalDowngradeNeutral—
28 Oct 2025RBC CapitalDowngradeSector Perform—
27 Oct 2025BernsteinDowngradeMarket Perform—
27 Oct 2025CitigroupDowngradeNeutral—
27 Oct 2025HC Wainwright & Co.DowngradeNeutral—
27 Oct 2025Leerink PartnersDowngradeMarket Perform—
27 Oct 2025NeedhamDowngradeHold—
27 Oct 2025Raymond JamesDowngradeMarket Perform—
22 Sept 2025Evercore ISI GroupMaintainsOutperform—
17 Sept 2025Roth CapitalInitiatesBuy—
15 Sept 2025B of A SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Atrium Therapeutics, Inc. (RNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.6×

Cheaper than 89% of US stocks

Price / sales
6.3×

Cheaper than 21% of US stocks

Price / book
1.0×

Cheaper than 75% of US stocks

EV / EBITDA
0.5×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−21.9%

Higher than 11% of US stocks

Earnings growth (YoY)
740.5%

Higher than 96% of US stocks

Gross margin
—
Operating margin
−752.9%

Higher than 6% of US stocks

Net margin
−184.1%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−37.0%

Higher than 25% of US stocks

Return on assets
−27.5%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNAAtrium Therapeutics, Inc.$225.8M
5
NERVMinerva Neurosciences, Inc.$225.5M
32
IMUXImmunic, Inc.$224.8M
38
TARAProtara Therapeutics, Inc.$227.5M
36
ABOSAcumen Pharmaceuticals, Inc.$228.2M
44
KROSKeros Therapeutics, Inc.$217.5M
71
SIONSionna Therapeutics, Inc.$236.1M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atrium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNA news & analysis

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 20 Aug 2026neutral

Atrium Therapeutics announced on August 20, 2026 that it awarded inducement grants to a newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan, consisting of non-qualified stock options for 11,000 shares at $13.48 per share and restricted stock units for 5,500 shares, both subject to vesting schedules tied to continued service.

Why it matters — RNA watchers would care because the equity incentive grants signal the company's efforts to attract and retain new talent, potentially affecting its share count and compensation structure.

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

PRNewsWire · 13 Aug 2026positive

Atrium Therapeutics reported its second quarter 2026 financial results, highlighting FDA clearance of its Investigational New Drug application for ATR 1072 and the launch of its Phase 1/2 Corventis trial, the first clinical study evaluating a potential disease-modifying treatment for PRKAG2 syndrome. The company also noted it achieved a second milestone payment under its global cardiovascular collaboration with Bristol Myers Squibb.

Why it matters — RNA watchers would care because the company is advancing its lead RNA-therapeutic candidate into the clinic and strengthening its BMS partnership, marking key progress in its precision cardiology pipeline.

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

PRNewsWire · 13 Aug 2026positive

Atrium Therapeutics announced it earned a $15 million milestone payment from Bristol Myers Squibb under their ongoing global cardiovascular collaboration, triggered by the successful delivery of a lead compound targeting an undisclosed cardiology indication. The announcement was made by President and CEO Kathleen Gallagher.

Why it matters — The payment signals continued progress in Atrium's partnership with Bristol Myers Squibb and advancement of its RNA therapeutics pipeline toward the cardiovascular space.

FAQ

Frequently asked questions about RNA stock

What is the RNA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Atrium Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNA stock a buy right now?

Of the 4 analysts covering Atrium Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atrium Therapeutics, Inc. 5 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNA?

As at 22 Aug 2026, Atrium Therapeutics, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (76 of 100).

Will RNA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +89.4% from the last close, and Ticker Nerd's factor model ranks Atrium Therapeutics, Inc. 5 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNA stock forecast for 2030?

No analyst covering Atrium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.

What does Atrium Therapeutics, Inc. do?

Avidity Biosciences Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), a novel class of RNA therapeutics that combine the specificity of monoclonal antibodies with the precision of oligonucleotides to target hard-to-reach tissues like skeletal and cardiac muscle.

What is the latest news on RNA?

The most recent item we track (PRNewsWire, 20 Aug 2026): "Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Atrium Therapeutics announced on August 20, 2026 that it awarded inducement grants to a newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan, consisting of non-qualified stock options for 11,000 shares at $13.48 per share and restricted stock units for 5,500 shares, both subject to vesting schedules tied to continued service.

Company

About Atrium Therapeutics, Inc.

Avidity Biosciences Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), a novel class of RNA therapeutics that combine the specificity of monoclonal antibodies with the precision of oligonucleotides to target hard-to-reach tissues like skeletal and cardiac muscle. This proprietary AOC platform enables targeted delivery of RNA-modulating therapies directly into cells, addressing the root causes of diseases previously challenging for existing RNA treatments. The company focuses on rare neuromuscular diseases, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD), with multiple programs in clinical development. Avidity Biosciences Inc. also advances initiatives in precision cardiology and immunology through internal discovery efforts and partnerships. Headquartered in San Diego, California, the company operates within the pharmaceutical preparation manufacturing segment, emphasizing innovative solutions for patients with unmet medical needs in muscle disease franchises and beyond.

CEO Ms. Kathleen P. Gallagher · 511 employees · United States · https://atriumtherapeutics.com